KRAS and neoplasm: In the retrospective analysis of our cohort, tissue KRAS mutational status at baseline could be confirmed in cfDNA in 80% of the therapy naïve patients (Fig 4A and 4B), highlighting the potential of this promising tool for noninvasive molecular assessment and underlining other concordance analyses of cfDNA and tumor tissue [13, 31].